Overview

Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)

Status:
Completed
Trial end date:
2016-05-25
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy of golimumab in maintaining a clinical response in participants with moderate-to-severe ulcerative colitis.
Phase:
Phase 4
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Antibodies, Monoclonal
Golimumab